Neuroendocrinology
Reproductive Neuroendocrinology
Allopregnanolone-Induced Modification of Presynaptic Basal and K+-Induced [3H]-Norepinephrine Efflux from Rat Cortical Slices during the Estrous CycleBelmar J.a · Cuellar C.a · Llona I.b · Arancibia S.c · Kusch C.a · Tapia-Arancibia L.c · Pinter A.a · Pérez H.aa Laboratory of Biochemical Pharmacology, P. Catholic University of Chile and b Laboratory of Neural Systems, University of Santiago, Chile; c Laboratory of Brain Plasticity EP 628, CRNS, University of Montpellier II, France
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: October 14, 1998
Issue release date: October 1998
Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 1
ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)
For additional information: https://www.karger.com/NEN
Abstract
Superfused frontal slices of cerebral cortex were preloaded with [3H]-norepinephrine ([3H]NE). Basal [3H]NE efflux and K+-induced [3H]NE release were studied during the estrous cycle and in the presence of neurosteroids. Basal [3H]NE efflux showed estrous cycle-related variations, with lowest values found during estrus and diestrus II. Allopregnanolone (10–9 M) potentiated basal [3H]NE efflux from the 1st minute of its application; the effect of the steroid was still present after 20 min. This effect was also dependent upon the estrous cycle, since basal [3H]NE efflux was mainly increased during estrus diestrus I, and to a lesser degree only during proestrus. During diestrus II and after ovariectomy, basal [3H]NE efflux was no longer affected by the neurosteroid. In the presence of yohimbine (10–6 M), the effect of allopregnanolone on basal efflux was potentiated only during the first 3 min but vanished thereafter. Allopregnanolone (10–9 M) potentiated the K+-induced [3H]NE release during estrus, but pregnenolone (10–9 M) was ineffective, suggesting specificity of the neurosteroid. Yohimbine (10–6 M) also potentiated K+-induced [3H]NE release. When applied simultaneously with allopregnanolone (10–9M), a potentiating effect on [3H]NE release was observed. The present results suggest that allopregnanolone is a neurosteroid able to modulate norepinephrine release in the cerebral cortex in an estrous cycle-dependent manner, and that the effect could involve noradrenergic alpha-2 receptors.
Related Articles:
References
-
McEwen B: Steroids and brain function. Trends Pharmacol Sci 1985;6:22–26.
External Resources
- Ramírez VD, Kim K, Dluzen D: Progesterone action on the LHRH and the nigrostriatal dopamine neuronal system: In vitro and in vivo studies. Recent Prog Horm Res 1985;41:421–472.
- Cabrera R, Díaz A, Pinter A, Belmar J: In vitro progesterone effects on [3H]dopamine release from rat corpus striatum slices obtained under different endocrine conditions. Life Sci 1993;53:1767–1777.
- Pinter A, Belmar J: In vitro progesterone effects on [3H]norepinephrine release from rat cerebral cortex slices. Neuroreport 1993;4:1203–1206.
- Baulieu EE, Schumacher M, Koening H, Jung-Testas I, Akwa Y: Progesterone as neurosteroid: Actions within the nervous system. Cell Mol Neurobiol 1996;16:143–154.
-
Robel P, Baulieu EE: Neurosteroids: Biosynthesis and function. Trends Endocr Metab 1994;5:1–8.
External Resources
- Paul SM, Purdy RH: Neuroactive steroids. FASEB J 1992;6:2311–2321.
-
Baulieu EE: Neurosteroids: Of the nervous system, by the nervous system, for the nervous system. Recent Prog Horm Res 1997;52:1–32.
- Tauboll E, Ottersen OP, Gjerstad L: The progesterone metabolite 5α-pregnan-3α-ol-20-one reduces K+-induced GABA and glutamate release from identified nerve terminals in rats hippocampus: A semiquantitative immunocytochemical study. Brain Res 1993;623:329–333.
- Finn DA, Gee KW: The influence of estrous cycle on neurosteroid potency at the gamma-aminobutyric acid A receptor complex. J Pharmacol Exp Ther 1993;265:1374–1379.
- Parada S, Galleguillos X, Forray MI, Belmar J: Changes of norepinephrine levels and release in rat cerebral cortex during the estrous cycle. Neuroreport 1991;2:801–804.
- Purdy RH, Morrow AL, Moore PH, Paul SM: Stress-induced elevations of γ-aminobutyric acid type A receptor active steroids in the rat brain. Proc Natl Acad Sci USA 1991;88:4553–4557.
- Wilson MA, Bircardi R: Sex differences in GABA/benzodiazepine receptor changes and corticosterone release after acute stress in rats. Exp Brain Res 1994;101:297–306.
- Arancibia S, Estupina C, Pesco J, Belmar J, Tapia-Arancibia L: Responsiveness to depolarization of hypothalamic neurons secreting somatostatin under stress and estrous cycle conditions: Involvement of GABAergic and steroidal interactions. J Neurosci Res 1997;50:575–584.
- Hoffman BB, Lefkowitz RJ: Alpha-adrenergic receptor subtypes. N Engl J Med 1980;302:1390–1396.
-
Starke K: Presynaptic receptors. Ann Rev Pharmacol Toxicol 1981;21:7–30.
-
Belmar J, Lara H, Cuellar C, Pérez H, Arancibia S: Alpha-2 receptors and allopregnanolone-induced modification of 3[H]-norepinephrine release from rat cerebral cortex slices under different endocrine conditions. 27th Annu Meet Soc for Neurosci, New Orleans, Oct 1997.
- Karkanias GB, Etgen AM: A thermodynamic analysis of estrogen regulation of alfa-2 adrenoceptor binding. Brain Res 1995;674:26–32.
-
Cooper JR, Bloom FE, Roth RH: Norepinephrine and epinephrine: in Cooper JR, Bloom FE, Roth RH (eds): The Biochemical Basis of Neuropharmacology, ed 7. New York, Oxford University Press, 1996, pp 226–292.
- Nicholas AP, Hökfelt T, Pieribone VA: The distribution and significance of CNS adrenoceptors examined with in situ hybridization. Trends Pharmacol Sci 1996;17:245–255.
- Dayanithi G, Tapia-Arancibia L: Rise in intracellular calcium via a nongenomic effect of allopregnanolone in fetal rat hypothalamic neurons. J Neurosci 1996;16:130–136.
- Petitti N, Etgen AM: Progesterone depression of norepinephrine-stimulated cAMP accumulation in hypothalamic slices. Brain Res Mol Brain Res 1989;5:109–119.
- Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR, Trendelenburg U: 4th International Union of Pharmacology Nomenclature of Adrenoceptors. Pharmacol Rev 1994;46:121–136.
- Majewska MD: Steroid regulation of the GABAA receptor: Ligand binding, chloride transport and behaviour. Ciba Found Symp 1990;153:83–97.
-
Monnet FP, Blier P, Debonnel G, de Montigny C: Modulation by sigma ligands of N-methyl-D-aspartate-induced (tritiated) noradrenaline release in the rat hippocampus: G-protein dependency. Naunyn Schmiedeberg’s Arch Pharmacol 1992;346:32–39.
- McEwen BS: Non-genomic and genomic effects on neural activity. Trends Pharmacol Sci 1991;12:141–147.
- Tapia-Arancibia L, Andrè M, Belmar J, Arancibia S: Neuroactive steroids modulate GABA inhibition of hypothalamic somatostatin release. Neuroreport 1995;6:1927–1931.
- Padem CM, McEwen BS, Fisman J, Snyder L, De Groff V: Competition by estrogens for catecholamines receptor binding in vitro. J Neurochem 1982;39:512–520.
Article / Publication Details
Published online: October 14, 1998
Issue release date: October 1998
Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 1
ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)
For additional information: https://www.karger.com/NEN
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
